Axsome Therapeutics, Inc. cash flow to debt ratio of -38.71% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Axsome Therapeutics, Inc.'s free cash flow has increased -27.04% from $-128.68M last year to $-93.89M, signaling increasing performance

Axsome Therapeutics, Inc.'s debt to equity ratio is 2.63, which means that the company's assets are unhealthy financed, signaling financial risk.

Axsome Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 3.38 last year to 2.63 today, signaling strengthened financials

Axsome Therapeutics, Inc. has a net cash position, so leverage is healthy.

Axsome Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Axsome Therapeutics, Inc.'s profit margin has increased (-66.86%) in the last year from -74.47% to -24.68%, signaling increasing performance

Axsome Therapeutics, Inc.'s short-term assets of $588.99M exceed its short-term liabilities of $378.84M

Axsome Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Axsome Therapeutics, Inc.'s return on equity of -255.60%, is lower than 15.00%, indicating bad performance

Axsome Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Axsome Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Axsome Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Axsome Therapeutics, Inc. has negative free cash flow, indicating cash burn

Axsome Therapeutics, Inc.'s yearly earnings has increased -36.22% since last year from $-287.22M to $-183.17M, signaling increasing performance

Axsome Therapeutics, Inc.'s yearly revenue has increased 65.55% since last year from $385.69M to $638.50M, signaling increasing performance

ROIC -50.73% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Axsome Therapeutics, Inc.'s 3-year revenue CAGR of 133.68% is positive, indicating growing revenue over the past 3 years

Axsome Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Axsome Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Axsome Therapeutics, Inc. has insufficient data to evaluate this check.

Axsome Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Axsome Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Axsome Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Axsome Therapeutics, Inc. has insufficient data to evaluate this check.

Axsome Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Axsome Therapeutics, Inc. has a price-to-book ratio of 136.56x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Axsome Therapeutics, Inc. has a price-to-sales ratio of 14.65x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue